Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.5%
0%
20.5%
6 Months
162.16%
0%
162.16%
1 Year
43.7%
0%
43.7%
2 Years
-24.66%
0%
-24.66%
3 Years
-27.61%
0%
-27.61%
4 Years
-23.32%
0%
-23.32%
5 Years
-19.75%
0%
-19.75%
ODI Pharma AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
42.12%
EBIT Growth (5y)
-9.73%
EBIT to Interest (avg)
-4.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.00
Sales to Capital Employed (avg)
6.67
Tax Ratio
1.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
1.48
EV to Sales
-0.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
524.73%
ROE (Latest)
-603.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Jun'25
Change(%)
Net Sales
10.90
0.00
Operating Profit (PBDIT) excl Other Income
1.40
-1.60
187.50%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.30
-1.70
176.47%
Operating Profit Margin (Excl OI)
130.70%
-245,378.90%
24,550.96%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 176.47% vs -466.67% in Jun 2025
Annual Results Snapshot (Consolidated) - Jun'25
Jun'25
Jun'24
Change(%)
Net Sales
3.10
22.30
-86.10%
Operating Profit (PBDIT) excl Other Income
-5.30
-1.90
-178.95%
Interest
0.70
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.90
-0.60
-883.33%
Operating Profit Margin (Excl OI)
-1,683.00%
-86.30%
-159.67%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2025 is -86.10% vs 22,200.00% in Jun 2024
Consolidated Net Profit
YoY Growth in year ended Jun 2025 is -883.33% vs 91.30% in Jun 2024
About ODI Pharma AB 
ODI Pharma AB
Pharmaceuticals & Biotechnology
Odi Pharma AB (publ) is a Swedish-based pharmaceutical company. The Company is a manufacturer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. The Company is located in Stockholm.
Company Coordinates 
Company Details
Engelbrektsgatan 9-11 , STOCKHOLM None : 114 32
Registrar Details






